Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q2 2021 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Aug 05, 2021 / 08:30PM GMT
Release Date Price: €11.19
Operator

Hello, and welcome to the Aurinia Pharmaceuticals second quarter earnings call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Glenn Schulman, Head of Investor Relations. Please go ahead.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thanks, Kevin, and thanks all for joining us today as we discuss Aurinia's second quarter financial results. Joining me on the call this afternoon are Peter Greenleaf, President and CEO; Joe Miller, our Chief Financial Officer; Max Colao, our Chief Commercial Officer; and Neil Solomons, our Chief Medical Officer here at Aurinia.

Our agenda for today, Peter will provide a review of the LUPKYNIS launch date, our outlook for the rest of the year, along with our ongoing clinical and regulatory activities. From there, Joe will discuss our financial performance in more detail and then after some closing remarks from Peter, the whole team will be here and available for your questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot